RYR2 and catecholaminergic polymorphic ventricular tachycardia: These included studies on murine gain of function, RyR2-P2328S, catecholaminergic polymorphic ventricular tachycardic (CPVT) and loss-of-function Pgc1β−/− paradigms for pro-arrhythmic metabolic cardiac disease.